story of the week
Dapagliflozin in Patients With Cardiometabolic Risk Factors Hospitalised With COVID-19
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Diabetes & Endocrinology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Dapagliflozin in Patients With Cardiometabolic Risk Factors Hospitalised With COVID-19 (DARE-19): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial
Lancet Diabetes Endocrinol 2021 Jul 21;[EPub Ahead of Print], MN Kosiborod, R Esterline, RHM Furtado, J Oscarsson, SB Gasparyan, GG Koch, F Martinez, O Mukhtar, S Verma, V Chopra, J Buenconsejo, AM Langkilde, P Ambery, F Tang, K Gosch, SL Windsor, EE Akin, RVP Soares, DDF Moia, M Aboudara, CR Hoffmann Filho, ADM Feitosa, A Fonseca, V Garla, RA Gordon, A Javaheri, CP Jaeger, PE Leaes, M Nassif, M Pursley, FS Silveira, WKS Barroso, JR Lazcano Soto, L Nigro Maia, O BerwangerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.